SHORT REPORTSLung function improvement in asthma with a cysteinylleukotriene receptor antagonist
References (11)
- et al.
The effect of an oral leukotriene D4 antagonist L-649,923 on the response to inhaled antigen in asthma
J Allergy Clin Immunol
(1987) - et al.
Effect of the oral leukotriene D4 antagonist LY.171883 on inhaled and intradermal antigen and LTD4 in atopic subjects
J Clin Allergy Immunol
(1989) Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation
Science
(1983)- et al.
Comparative effects of inhaled leukotriene C4, leukotriene D4 and histamine in normal human subjects
Thorax
(1984) Standardised lung function testing
Bull Eur Physiopathol Respir
(1983)
Cited by (200)
Leukotriene Receptor Antagonists and Risk of Neuropsychiatric Entities: A Meta-Analysis of Observational Studies
2023, Journal of Allergy and Clinical Immunology: In PracticeCurrent state and future prospect of the therapeutic strategy targeting cysteinyl leukotriene metabolism in asthma
2019, Respiratory InvestigationCitation Excerpt :Table 2 enumerates the therapeutic effects of LTRAs on long-term asthma management. The therapeutic effects of LTRAs on improving the respiratory function and quality of life in patients with mild asthma are similar to those of ICSs [55–58]. These agents also possess anti-inflammatory properties and reduce the number of eosinophils, lymphocytes, and mast cells in sputum and bronchial biopsy tissue [59], while also decreasing the levels of fractional exhaled nitric oxide (FeNO), which is a biomarker that reflects airway eosinophilic inflammation [60,61].
Patient stratification and the unmet need in asthma
2017, Pharmacology and TherapeuticsInundation of asthma target research: Untangling asthma riddles
2016, Pulmonary Pharmacology and TherapeuticsEvaluating the role of leukotriene-modifying drugs in asthma management: Are their benefits ‘losing in translation’?
2016, Pulmonary Pharmacology and TherapeuticsCitation Excerpt :Since, 5-LO inhibitors block the synthesis of LTs, it is assumed that such agents might deliver better efficacy than the cys-LT1 receptor antagonists. Zileuton evolved as the first evidence of 5-LO inhibitor that could suppress allergen-induced eosinophilia in the lungs and administer both acute and chronic improvement of lung function in asthma [41]. The acute improvement in FEV1 is fairly comparable in magnitude to that observed with the cys-LT1 receptor antagonists and is observed within hours of the first oral dose [42].
Pulmonary Mast Cells
2015, Comparative Biology of the Normal Lung: Second Edition